Comparing and combining TSPO-PET tracers in tauopathies
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Purpose
Neuroinflammation is a key pathological driver in neurodegenerative diseases, including Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP). Positron emission tomography (PET) with tracers targeting the translocator protein (TSPO) enables the in vivo quantification of microgliosis. Different TSPO tracers have shown similar patterns across disease-specific cohorts. However, direct quantitative comparisons between commonly used TSPO-PET tracers in tauopathies have not been performed. Here, we apply our TSPO-PET standardization pipeline across clinically matched AD and PSP cohorts, to quantify, compare and combine multi-centre TSPO-PET data.
Methods
Patients with PSP were scanned with either [ 11 C]PK11195 or [ 18 F]GE-180 at one of two centres, while patients with AD and control participants were scanned with either [ 11 C]PK11195, [ 18 F]GE-180 or [ 11 C]PBR28 at one of three centres. A standardised pre-processing pipeline was implemented and participant standardised uptake volume ratio (SUVR) values were z-scored using tracer-specific control participant values. In a data-driven approach, dissimilarity analyses were employed to assess differences between tracers across clinically matched cohorts.
Results
In PSP, dissimilarity analysis suggested that [ 11 C]PK11195 and [ 18 F]GE-180 were comparable following standardisation. In AD, comparability across tracers was less robust, with [ 11 C]PK11195 and [ 18 F]GE-180 being most comparable, followed by [ 18 F]GE-180 vs [ 11 C]PBR28, then by [ 11 C]PK11195 vs [ 11 C]PBR28.
Conclusion
The pipeline was effective at harmonising TSPO-PET tracers and standardising the regional quantification of neuroinflammation in clinically matched cohorts of PSP, while the standardisation pipeline results were less robust across AD cohorts.
